Ohtuvayre (Ensifentrine) Patent Expiration, LOE Window & CMS Spending

Ohtuvayre (Ensifentrine) by Merck & Co.: FDA Orange Book core substance LOE 2031-08-21 (last listed 2044-06-25), 0 AB generics, $2.1M 2024 CMS Part D & Medicaid spend, and $2,950 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN217389 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-08-21
Last Listed Patent or Exclusivity Date2044-06-25
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.1M
2024 Medicare Part D Spend$113K
2024 Medicaid Spend$2.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,950 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.